- Conditions
- Depressive Disorder, Major
- Interventions
- saredutant (SR48968), paroxetine, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Opioid Use Disorder, HIV, Hepatitis C Virus, Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infection, Integrated Care, Medications for Opioid Use Disorder
- Interventions
- Integrated care
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2028 – 2029
- U.S. locations
- 1
- States / cities
- Northport, New York
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Symptoms and Signs, Physical Inactivity, Muscle Loss
- Interventions
- LiverWatch Intervention
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Philadelphia, Pennsylvania
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration, Magnetic Resonance Imaging
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Albert Lea, Minnesota • Mankato, Minnesota + 3 more
- Conditions
- Mesothelioma
- Interventions
- LMB-100, ipilimumab, Diphenhydramine, Famotidine, Acetaminophen, Dexamethasone, Biopsy, FDG-PET, CT CAP, MRI, ECG, Echocardiogram
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Interventions
- carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies
- Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hepatitis C Virus Infection
- Interventions
- SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
- Interventions
- M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
- Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Food Allergy
- Interventions
- FAHF-2 (TM)
- Drug
- Lead sponsor
- Li, Xiu-Min, M.D.
- Individual
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • New York, New York
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 27
- States / cities
- Goodyear, Arizona • Peoria, Arizona • Huntington Beach, California + 22 more
- Conditions
- Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
- Interventions
- Finerenone, Sotagliflozin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Portland, Oregon
- Conditions
- Hypovitaminosis D
- Interventions
- Standing Phototherapy Kiosk, D3 Oral supplement
- Device · Dietary Supplement
- Lead sponsor
- Madigan Army Medical Center
- Federal
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Liposomal doxorubicin, Dexamethasone
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Detroit, Michigan
- Conditions
- SLE; Drug
- Interventions
- KPG-818 low dose, KPG-818 mid dose, KPG-818 high dose, Placebo
- Drug
- Lead sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Lenvatinib, Pembrolizumab, Oral Placebo, IV Placebo, TACE
- Drug · Biological · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
- Interventions
- Ruxolitinib, BCR-ABL Tyrosine Kinase Inhibitor (TKI)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Atlanta, Georgia • Montvale, New Jersey + 5 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
- Conditions
- T-cell Lymphoma
- Interventions
- Enasidenib, Rituximab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
- Conditions
- Male Osteoporosis
- Interventions
- Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
- Drug · Dietary Supplement
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years to 85 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
- Interventions
- Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs
- Dietary Supplement · Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Gastroparesis
- Interventions
- Pioglitazone 30 mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Lymphocytic Leukemia, Richter's Transformation
- Interventions
- Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
- Drug
- Lead sponsor
- Christine Ryan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Batefenterol + Fluticasone Furoate, Placebo, Albuterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
- Conditions
- Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
- Interventions
- Photobiomodulation, Routine Oral Care and Analgesia
- Device · Other
- Lead sponsor
- MuReva Phototherapy Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Long Beach, California • Miami, Florida + 9 more